Table 1. CIRM grants. Below is a list of 14 research grants awarded by the California Institute for Regenerative Medicine (CIRM) to develop stem cell-based therapies.

 

Lead institution

 

Lead principal investigator

 

CIRM
funding ($M)

 

Proposal summary

 

Cedars-Sinai Medical Center

 

Eduardo Marbán

 

5.6

 

Repair heart tissue damaged by heart attack using autologous heart stem cells

 

City of Hope

 

Karen Aboody

 

18.0

 

Treat brain tumors using neural stem cells modified to carry a tumor-killing drug

 

City of Hope

 

John Zaia

 

14.6

 

Treat HIV using genetically modified autologous hematopoietic stem cells that give rise to HIV-resistant T cells

 

Novocell Inc.

 

Emmanuel Baetge

 

20.0

 

Treat type 1 diabetes by implanting islet cells generated from human embryonic stem cells (hESCs)

 

Salk Institute for Biological Studies

 

Samuel Pfaff

 

15.6

 

Treat amyotrophic lateral sclerosis (ALS) by implanting precursor astrocyte cells derived from hESCs

 

Stanford University

 

Alfred Lane

 

11.7

 

Treat epidermolysis bullosa using genetically modified induced pluripotent stem cells derived from the patient's skin cells

 

Stanford

 

Gary Steinberg

 

20.0

 

Treat stroke using implanted neural stem cells derived from hESCs

 

Stanford

 

Irving Weissman

 

20.0

 

Develop a mAb that targets leukemia stem cells

 

University of California, Los Angeles (UCLA)

 

Irvin ChenA

 

20.0

 

Treat HIV using RNAi-modified autologous hematopoietic stem cells that give rise to HIV-resistant T cells

 

UCLA

 

Donald Kohn

 

9.2

 

Treat sickle cell disease using genetically modified hematopoietic stem cells that become normal red blood cells

 

UCLA

 

Dennis Slamon

 

20.0

 

Develop compounds that target cancer stem cells in solid tumors

 

University of California, San Diego

 

Dennis Carson

 

20.0

 

Develop mAbs and small molecules that destroy leukemia stem cells

 

University of California, San Francisco

 

Mitchel Berger

 

19.2

 

Treat brain tumors using neural stem cells modified to carry a tumor-killing drug

 

University of Southern California

 

Mark Humayun

 

15.9

 

Treat macular degeneration using transplanted retinal cells derived from hESCs

 

Total

 

 

229.8

 

 

AGeoff Symonds at biotech company Calimmune Inc. is also a principal investigator.